What question did this study set out to answer?

To evaluate the efficacy and safety of various doses of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin.

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and safety of various doses of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin.
Multicentre, double-blind, randomized, placebo-controlled design over 12 weeks.
Participants received one of four doses of ipragliflozin or placebo, with a focus on changes in HbA1c levels.
Adverse events and safety measurements were tracked throughout the study.
Ipragliflozin reduced HbA1c levels from baseline by up to -0.48% at 300 mg compared to placebo (p<0.05).
Weight loss and blood pressure reductions were significant across ipragliflozin treatment groups.
AEs occurred in 39.7-51.4% of ipragliflozin patients, comparable to 39.4% in placebo, with no dose dependency.

No takes yet. Share an insight, caveat, or question.

Randomized trial assesses efficacy and safety of ipragliflozin in type 2 diabetes patients, suggesting improvement in glycaemic control.

Wilding et al. (2012) studied this question.

View Full Paper

Ask AI

Bookmark